Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA Single Cell Sequencing of Colorectal Liver Metastasis regarding their Histopathological Growth Pattern

ABSTRACT: RNA Single Cell Sequencing of Colorectal Liver Metastasis regarding their Histopathological Growth Pattern

PROVIDER: PRJEB55156 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNA Single Cell Sequencing of Colorectal Liver Metastasis regarding their Histopathological Growth Pattern

Project description:Molecular characterization of single cells in Colorectal Cancer Liver Metastases (CRCLM) and corresponding healthy liver tissue focusing on the comparison between the two main histopathological growth patterns (HGPs): desmoplastic HGP (dHGP) and replacement HGP (rHGP) with the intent to identify possible biomarkers or treatment targets especially for the more aggressive replacement HGP.

2023-01-05 | E-MTAB-12022 | biostudies-arrayexpress

RNA Spatial Sequencing of Colorectal Liver Metastases regarding their Histopathological Growth Patterns

Project description:RNA Spatial Sequencing of Colorectal Liver Metastases regarding their Histopathological Growth Patterns

| PRJEB55171 | ENA

RNA Spatial Sequencing of Colorectal Liver Metastases regarding their Histopathological Growth Patterns

Project description:Molecular characterization of tissue areas in Colorectal Cancer Liver Metastases (CRCLM) and adjacent healthy liver tissue focusing on the comparison between the two main histopathological growth patterns (HGPs): desmoplastic HGP and replacement HGP with the intent to identify possible biomarkers or treatment targets especially for the more aggressive replacement HGP.

2023-01-05 | E-MTAB-12043 | biostudies-arrayexpress

Steatosis shifts the histopathological heterogeneity of liver metastases towards poor prognosis replacement growth in colorectal cancer patients

Project description:Liver metastases are a leading cause of cancer-related deaths, particularly in colorectal cancer. Two distinct histological growth patterns characterize liver metastases: the desmoplastic growth pattern, marked by a stromal encapsulating ring around the metastasis, and the replacement growth pattern, where cancer cells integrate into and replace the native hepatocyte architecture. The replacement pattern is associated with poorer therapeutic responses and worse overall prognosis. Concurrently, obesity, which alters the liver microenvironment, is linked to unfavorable outcomes in colorectal cancer patients. This study explores the interplay between a lipid-rich liver microenvironment and histological growth patterns in metastases. Using resected patient specimens and preclinical mouse models of obesity, we observed a correlation between liver steatosis and a shift toward the more aggressive replacement growth pattern. Mechanistically, lipid-rich environments, both in vitro and in vivo, were found to enhance proline synthesis in colorectal cancer cells, promoting extracellular matrix (ECM) production. This phenotypic switch is driven by fatty acid oxidation, which generates acetyl-coenzyme A, leading to the accumulation of the transcription factor MYC. Inhibiting fatty acid oxidation or silencing MYC reversed the aggressive growth advantage in lipid-rich conditions. Interestingly, cancer cells lose the aggressive phenotype once the lipid abundance is withdrawn. Furthermore, publicly available patient datasets revealed upregulated proline and ECM metabolism in inherent replacement growth patterns. Targeting these pathways significantly reduced liver metastasis outgrowth in preclinical models.

2026-04-22 | GSE292820 | GEO

Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer

Project description:There is a paucity of data on the histopathological response of peritoneal tumor deposits from colorectal cancer to neoadjuvant chemotherapy. Particularly, no prospective assessment of chemotherapy-associated histopathological response within the peritoneum has been performed so far. Therefore, there is an urgent need to conduct a clinical trial aimed at prospectively assessing the histopathological response within the peritoneum in patients with peritoneal metastasis from colorectal cancer. Recently, Loupakis et al. reported that the triplet regimen of 5-fluorouracil, oxaliplatin and irinotecan (FOLFOXIRI) in combination with bevacizumab significantly improved median progression-free survival in metastatic colorectal cancer patients from 9.7 to 12.1 months as compared with fluorouracil, leucovorin, and irinotecan (FOLFIRI) + bevacizumab. In view of these data, it is likely that FOLFOXIRI + bevacizumab will also lead to a significant improvement of the histopathological response within the peritoneum of patients with peritoneal metastasis from colorectal cancer (pcCRC) as compared with previous standard chemotherapy. The investigators hypothesize that FOLFOXIRI + bevacizumab will induce a pCR or major response in peritoneal tumor deposits in >30% of patients (taking the response rate to FOLFOX- or FOLFIRI-based neoadjuvant chemotherapy from the published literature as a reference).

| 2201320 | ecrin-mdr-crc